Effect of an antimicrobial stewardship bundle for patients with Clostridium difficile infection

被引:26
|
作者
Brumley, Paul E. [1 ]
Malani, Anurag N. [2 ,3 ]
Kabara, Jared J. [4 ]
Pisani, Jennifer [5 ]
Collins, Curtis D. [1 ]
机构
[1] St Joseph Mercy Hlth Syst, Dept Pharm Serv, 5301 East Huron River Dr, Ann Arbor, MI USA
[2] St Joseph Mercy Hlth Syst, Div Infect Dis, Dept Internal Med, 5301 East Huron River Dr, Ann Arbor, MI USA
[3] St Joseph Mercy Hlth Syst, Dept Infect Prevent & Control, 5301 East Huron River Dr, Ann Arbor, MI USA
[4] St Joseph Mercy Hlth Syst, Qual Inst, 5301 East Huron River Dr, Ann Arbor, MI USA
[5] Univ Michigan, Coll Pharm, 428 Church St, Ann Arbor, MI 48109 USA
关键词
HEALTH-CARE EPIDEMIOLOGY; PRACTICE GUIDELINES; DISEASES SOCIETY; MANAGEMENT; IMPACT; METRONIDAZOLE; ASSOCIATION; AMERICA; PROGRAM; RISK;
D O I
10.1093/jac/dkv404
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The study objective was to determine whether there was an improvement in compliance with recommended Clostridium difficile infection (CDI) treatment after introduction of an institutional CDI bundle with daily antimicrobial stewardship assessment. This was a single-centre, quasi-experimental study evaluating compliance with an antimicrobial stewardship team-implemented care bundle in patients with CDI compared with historical controls. The primary outcome, compliance with overall bundle elements, was achieved when the following measures were accomplished: (i) appropriate CDI antimicrobial therapy based on the institutional treatment algorithm; (ii) discontinuation of acid-suppressant therapy in the absence of a pre-specified indication; and (iii) discontinuation of unnecessary antimicrobials. Secondary objectives were to evaluate the extent to which antimicrobial stewardship involvement affected treatment compliance and to assess trends in CDI clinical outcomes, such as mortality and readmission. One-hundred-and-sixty-nine patients were evaluated; 83 after implementation of the care bundle (bundle group) and 89 prior to bundle implementation (historical control group). Compliance with overall bundle endpoints was significantly higher in the bundle group versus the control group (81% versus 45%, PaEuroS < aEuroS0.001). Individual bundle components that were significantly improved in the bundle group were discontinuation of non-essential acid suppressants (90% versus 18%, PaEuroS < aEuroS0.001) and administration of appropriate CDI therapy (82% versus 64%, PaEuroS < aEuroS0.009). No significant differences were observed in overall or CDI-related mortality or readmissions, durations of therapy or reduction of non-essential concomitant antimicrobials. Introduction of an antimicrobial stewardship bundle for CDI significantly improved adherence to institutional treatment recommendations and overall management of patients with CDI.
引用
收藏
页码:836 / 840
页数:5
相关论文
共 50 条
  • [31] Isolation of patients with Clostridium difficile infection
    Wilcox, M
    Settle, C
    Fawley, W
    Parnell, P
    Porter, C
    Keer, V
    Hawkey, P
    JOURNAL OF HOSPITAL INFECTION, 1997, 37 (04) : 331 - 334
  • [32] Clostridium difficile infection in ICU patients
    E Belesiotou
    C Routsi
    M Nepka
    E Magira
    P Kaltsas
    Z Psaroudaki
    E Kraniotaki
    A Argyropoulou
    T Pittaras
    S Zakynthinos
    Critical Care, 18 (Suppl 1):
  • [33] Clostridium Difficile Infection in Patients With Cancer
    Winkeljohn, Debra
    CLINICAL JOURNAL OF ONCOLOGY NURSING, 2011, 15 (02) : 215 - 217
  • [34] Clostridium difficile infection in dialysis patients
    Tirath, Ankita
    Tadros, Sandra
    Coffin, Samuel L.
    Kintziger, Kristina W.
    Waller, Jennifer L.
    Baer, Stephanie L.
    Colombo, Rhonda E.
    Huber, Lu Y.
    Kheda, Mufaddal F.
    Nahman, N. Stanley, Jr.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2017, 65 (02) : 353 - 357
  • [35] Clostridium difficile infection in cancer patients
    Angel Sanchez-Munoz, Luis
    Martin Asenjo, Miguel
    Martin Guerra, Javier
    MEDICINA CLINICA, 2017, 148 (02): : 91 - 91
  • [36] Alpha diversity in patients with Clostridium difficile infection and asymptomatic carriers of Clostridium difficile
    Sanchez Pellicer, P.
    Navarro Lopez, V.
    CLINICA CHIMICA ACTA, 2019, 493 : S539 - S539
  • [37] Characterization of Continued Antibacterial Therapy After Diagnosis of Hospital-Onset Clostridium difficile Infection: Implications for Antimicrobial Stewardship
    Harpe, Spencer E.
    Inocencio, Timothy J.
    Pakyz, Amy L.
    Oinonen, Michael J.
    Polk, Ronald E.
    PHARMACOTHERAPY, 2012, 32 (08): : 744 - 754
  • [38] An Antimicrobial Stewardship Program's Real-World Experience with Fidaxomicin for Treatment of Clostridium difficile Infection: A Case Series
    Vargo, Craig A.
    Bauer, Karri A.
    Mangino, Julie E.
    Johnston, Jessica E. W.
    Goff, Debra A.
    PHARMACOTHERAPY, 2014, 34 (09): : 901 - 909
  • [39] Community Clostridium difficile Clostridium difficile infection
    Wilcox, Mark H.
    Planche, Tim
    BRITISH MEDICAL JOURNAL, 2009, 338
  • [40] Institutional review of the implementation and use of a Clostridium difficile infection bundle and probiotics in adult trauma patients
    Bommiasamy, Aravind K.
    Connelly, Christopher
    Moren, Alexi
    Dodgion, Chris
    Bestall, Kelsey
    Cline, Anthony
    Martindale, Robert G.
    Schreiber, Martin A.
    Kiraly, Laszlo N.
    AMERICAN JOURNAL OF SURGERY, 2018, 215 (05): : 825 - 830